Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-ROR1/anti-CD3/anti-HSA trispecific antibody NM32-2668

A trispecific antibody directed against the tumor-associated antigen (TAA) receptor tyrosine kinase-like orphan receptor 1 (ROR1), the T-cell surface antigen CD3 and human serum albumin (HSA), with potential immunostimulating and antineoplastic activities. Upon administration, anti-ROR1/anti-CD3/anti-HSA trispecific antibody NM32-2668 binds to both ROR1 expressed on tumor cells and CD3 expressed on cytotoxic T lymphocytes (CTLs). This activates and redirects CTLs to ROR1-expressing tumor cells, which results in the CTL-mediated death of ROR1-expressing tumor cells. Anti-ROR1/anti-CD3/anti-HSA trispecific antibody NM32-2668 also binds to HSA, which prolongs the half-life of the agent. ROR1, also known as neurotrophic tyrosine kinase, receptor-related 1 (NTRKR1), is expressed during embryogenesis and in many types of hematological malignancies. It plays key roles in tumor cell proliferation and survival.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-ROR1/CD3/HSA trispecific antibody NM32-2668
ROR1 x CD3 x HSA T-cell engager NM32-2668
ROR1 x CD3 x HSA TCE NM32-2668
ROR1 x CD3 x HSA trispecific antibody NM32-2668
ROR1-targeting TCE NM32-2668
Code name:NM32 2668
NM32-2668
NM322668
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search